Abstract
Citrullinaemia is an autosomal recessive disorder caused by the deficiency of argininosuccinate synthase. The deficiency of this enzyme results in an interruption in the urea cycle and the inability to dispose of excess ammonia derived from the metabolism of protein. The only treatment for this disorder has been dietary restriction of protein and supplementation with medications allowing for alternative excretion of excess nitrogen. Gene therapy offers the possibility of a long-term cure for disorders like citrullinaemia by expressing the deficient gene in the target organ. We have explored the use of adenoviral vectors as a treatment modality for citrullinaemia in two animal models, a naturally occurring bovine model and a murine model created by molecular mutagenesis. Mice treated with adenoviral vectors expressing argininosuccinate synthase lived significantly longer than untreated animals (11 days vs 1 day); however, the animals did not exhibit normal weight gain during the experiment, indicating that the therapeutic effectiveness of the transducing virus was suboptimal. It is speculated that part of the failure to observe better clinical outcome might be due to the deficiency of arginine. In the bovine model, the use of adenoviral vectors did not result in any change in the clinical condition of the animals or in the level of plasma ammonia. However, the use of 15N isotopic ammonia allowed us to assess the flux of nitrogen through the urea cycle during the experiment. These studies revealed a significant increase in the flux through the urea cycle following administration of adenoviral vectors expressing argininosuccinate synthase. We conclude that the use of adenoviral vectors in the treatment of citrullinaemia is a viable approach to therapy but that it will be necessary to increase the level of transduction and to increase the level of enzyme produced from the recombinant viral vector. Future experiments will be designed to address these issues.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Batshaw ML, Yudkoff M, Mclaughlin BA, et al (1995) The sparse fur mouse is a model for gene therapy in ornithine carbamoyltransferase deficiency. Gene Ther 2: 743-749.
Beaudet AL, O'Brien WE, Bock H-GO, Freytag SO, Su T-S (1986) The human argininosuccinate synthetase locus and citrullinemia. Adv Hum Genet 15: 161-196.
Bett AJ, Haddara W, Prevec L, Graham FL (1994) An efficient and flexible system for construction of adenoviruses with insertions or deletions in early regions. Proc Natl Acad Sci USA 91: 8802-8806.
Brusilow SW, Horwich AL (1995) Urea cycle enzymes. In Scriver CR, Beaudet AL, Sly WL, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1187-1232.
Brusilow SW, Maestri NE (1996) Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 43: 127-170.
Dennis JA, Healy PJ, Beaudet AL, O'Brien WE (1989) Molecular definition of bovine argininosuccinate synthetase deficiency. Proc Natl Acad Sci USA 86: 7947-7951.
Featherston WR, Rogers QR, Freedland RA (1973) Relative importance of kidney and liver in synthesis of arginine by the rat. Am J Physiol 224: 127-129.
Graham FL (1991) Gene transfer and expression protocols. In Murray EJ, ed. Methods in Molecular Biology. Clifton, NJ: Humana Press, 109-128.
Graham FL, Smiley J, Russel WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Virology 36: 59-74.
Harper PAW, Healy PJ, Dennis JA, O'Brien JJ, Rayward DH (1986) Citrullinemia as a cause of neurological disease in neonatal Friesian calves. Aust Vet J 63: 378-379.
Jackson MJ, Kobayashi K, Beaudet AL, O'Brien WE (1989) Analysis of deletions at the human argininosuccinate synthetase locus. Mol Biol Med 6: 179-186.
Jahoor F, Burrin DG, Reeds PJ, Frazer M (1994) Measurement of plasma protein synthesis rate in infant pig: an investigation of alternative tracer approaches. Am J Physiol 267: R221-R227.
Katkin JP, Gilbert BE, Langston C, French K, Beaudet AL (1995) Aerosol delivery of a beta-galactosidase adenoviral vector to the lungs of rodents. Hum Gene Ther 6: 985-995.
Kiwaki K, Kanegae Y, Saito I, et al (1996) Correction of ornithine transcarbamylase deficiency in adult sp149-1ash mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter. Hum Gene Ther 7: 821-830.
Kobayashi K, Rosenbloom C, Beaudet AL, O'Brien WE (1991) Additional mutations in argininosuccinate synthetase causing citrullinemia. Mol Biol Med 8: 95-100.
Kobayashi K, Kakinoki H, Fukushige T, Shaheen N, Terazono H, Saheki T (1995) Nature and frequency of mutations in the argininosuccinate synthetase gene that cause classical citrullinemia. Hum Genet 96: 454-463.
Maestri NE, Clissold DB, Brusilow SW (1995) Long-term survival of patients with argininosuccinate synthetase deficiency. J Pediatr 127: 929-935.
McMurray WC, Mohyuddin F, Rossiter RM, et al (1962) Citrullinuria: a new aminoaciduria associated with mental retardation. Lancet 1: 138.
Michel JL, Rabier D, Rambaud C, et al (1994) Intrasplenic transplantation of hepatocytes in spf-ash mice with congenital ornithine transcarbamylase deficiency. Chirurgie 119(10): 666- 711.
Morris JG, Rogers QR (1978) Ammonia intoxication in the near-adult cat as a result of a dietary deficiency of arginine. Science 199: 431-432.
Morris JG, Rogers QR, Winterrowd DL, Kamikawa EM (1979) The utilization of ornithine and citrulline by the growing kitten. J Nutr 109: 724-729.
Morsy MA, Zhao JZ, Ngo TT, et al (1997) Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes. J Clin Invest 97: 826-832.
Northrup H, Beaudet AL, O'Brien WE (1990) Prenatal diagnosis of citrullinemia: review of a ten year experience including recent use of DNA analysis. Prenat Diagn 10: 771-779.
Patejunas G, Bradley A, Beaudet AL, O'Brien WE (1994) Generation of a mouse model for citrullinemia by targeted disruption of the argininosuccinate synthetase gene. Somatic Cell Mol Genet 20: 55-60.
Soriano P, Montgomery C, Geske R, Bradley A (1991) Targeted disruption of the c-src protooncogene leads to osteopetrosis in mice. Cell 64: 693-702.
Stratford-Perricaudet LD, Levrero M, Chasse J-F, Perricaudet M, Briand P (1990) Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1: 241-256.
Su T-S, Bock H-G, O'Brien WE, Beaudet AL (1981) Cloning of cDNA for argininosuccinate synthetase mRNA and study of enzyme overproduction in a human cell line. J Biol Chem 256: 11826-11831.
Wakabayashi Y, Yamada E, Yoshida T, Takahashi H (1994) Arginine becomes an essential amino acid after massive resection of rat small intestine. J Biol Chem 269: 32667-32671.
Wang T, Lawler AM, Steel G, Sipila I, Milam AH, Valle D (1995) Mice lacking ornithine-δ-amino-transferase have paradoxical neonatal hypoornithinaemia and retinal degeneration. Nature Genetics 11: 185-190.
Ye X, Robinson MB, Batshaw ML, Furth EE, Smith I, Wilson JM (1996) Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem 271(7): 3639-3646.
Ye X, Robinson MB, Pabin C, et al (1997) Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge. Pediatr Res 41: 527-534.
Yudkoff M, Daikhin Y, Nissim I, Jawad A, Wilson J, Batshaw M (1996) In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. J Clin Invest 98: 2167-2173.
Rights and permissions
About this article
Cite this article
Patejunas, G., Lee, B., Dennis, J.A. et al. Evaluation of gene therapy for citrullinaemia using murine and bovine models. J Inherit Metab Dis 21 (Suppl 1), 138–150 (1998). https://doi.org/10.1023/A:1005322010854
Issue Date:
DOI: https://doi.org/10.1023/A:1005322010854